Imunon’s (IMNN) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Imunon (NASDAQ:IMNN) in a research report report published on Monday,Benzinga reports. The firm currently has a $29.00 price objective on the stock.

Several other research analysts have also recently commented on IMNN. EF Hutton Acquisition Co. I upgraded shares of Imunon to a “strong-buy” rating in a report on Monday, September 23rd. HC Wainwright cut their price target on shares of Imunon from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Monday, November 11th.

Imunon Stock Performance

Shares of IMNN opened at $0.81 on Monday. Imunon has a 12 month low of $0.48 and a 12 month high of $3.65. The firm has a fifty day simple moving average of $0.94 and a 200 day simple moving average of $1.15. The stock has a market capitalization of $11.79 million, a price-to-earnings ratio of -0.43 and a beta of 2.14.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.